March 25, 2013

Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments

Creation of a new state-of-the-art industrial platform at Genzyme’s unit in Lyon

 

Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments
Creation of a new state-of-the-art industrial platform at Genzyme’s unit in Lyon

Paris and Strasbourg, France – March 25, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and Transgene SA (NYSE-Euronext: TNG) announced today a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene’s therapeutic products. The platform will be realized on Genzyme Polyclonals site in Lyon – Gerland area for an investment amount of 10 million euro equally financed by Sanofi and Transgene. The Platform will remain Sanofi’s exclusive property.